NATIVE. HUMAN. IMMUNOTHERAPY.
A natural match for the complexity of human disease.
Modern medicine struggles to keep pace with the emergence, mutation, and diversity of disease. The body’s natural defense system produces polyclonal antibodies against invaders such as viruses, allergens, bacteria, toxins, and other pathogens.
SAB Biotherapeutics has developed a first-of-its-kind therapeutic engine—unleashing the power of the body’s native biological defense system to produce immunotherapies that have the potential to truly match and overpower the complexity, diversity, and evolution of human disease.
This new class of immunotherapies opens the door to novel medicines that are potentially safer, more effective, and longer lasting than current antibody therapies.
The sophistication of science. The genius of nature.
Through remarkable genetic engineering, we've developed the DiversitAb™ platform to harness the native human antibody immune response. Our novel therapeutic engine can produce medicines—human polyclonal antibodies—for a broad array of pathogens to treat modern health challenges such as seasonal influenza, Type 1 diabetes, and cancers.
Advanced engineering and a refined suite of technologies optimized over nearly two decades
Broad therapeutic reach in autoimmunity, infectious disease, inflammation and oncology
Immunotherapies will never be the same.
No other immunotherapies so fully capture the power of the human humoral immune response with natural synergistic targeting to the complexity of disease. Our therapeutic engine is capable of rapidly generating fully human polyclonal antibodies at commercial scale, armed against targeted pathogens.
Natural, custom, high-potency immunotherapies with superior safety profile
Longer-lasting, broad spectrum activity compared to current antibody therapies
Robust, Clinical Stage Pipeline
Commercial Markets and Global Health Threats
Ready for rapid response. Because we can.
The speed and sophistication of our platform means we can address global health threats in ways only we can. We’re ready to respond quickly to epidemic-level pathogens, and we’re already developing treatments for some of the world’s most imminent health threats.
Awarded $27 million competitive contract from the U.S. Department of Defense to develop and test an accelerated and effective rapid response capability, at scale
Recognized as the only therapeutic platform to address priority pathogens by the World Health Organization
2301 E 60th St N
Sioux Falls, SD 57104
245 First Street, Suite 1836
Cambridge, MA 02142